🔎 Trials Near Me

Beranda › Kanker Paru Non-Sel Kecil › Florida › West Palm Beach

Uji klinis Kanker Paru Non-Sel Kecil di West Palm Beach, FL

13 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar West Palm Beach (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Menerima pesertaFase 2
  • Florida Cancer Specialists - East /ID# 271993, West Palm Beach
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06568939

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Menerima pesertaFase 3
  • Florida Cancer Specialists & Research Institute - East, West Palm Beach
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06881784

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Menerima pesertaFase 3
  • Florida Cancer Specialists - East, West Palm Beach
  • Florida Cancer Specialists, Palm Beach Gardens · 9 mi jauhnya
  • Florida Cancer Specialists, Wellington · 12 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07222566

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Menerima pesertaFase 2
  • Florida Cancer Specialists & Research Institute, West Palm Beach
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06667076

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Menerima pesertaFase 3
  • Florida Cancer Specialists East, West Palm Beach
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06890598

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Menerima pesertaFase 3
  • Florida Cancer Specialists - East, West Palm Beach
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06561386

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Menerima pesertaFase 3
  • Clinical Study Site, West Palm Beach
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06767514

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Menerima pesertaFase 2/3
  • SCRI - Florida Cancer Specialists - West Palm Beach, West Palm Beach
  • Local Institution - 007-926-A, Wellington · 12 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04613596

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Menerima pesertaFase 3
  • Research Site, West Palm Beach
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07291037

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Menerima pesertaFase 1/2
  • USOR Florida Cancer Specialists East, West Palm Beach
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT05579366

Uji klinis Kanker Paru Non-Sel Kecil di kota lain

Studi lain di West Palm Beach

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.